Louis Fisher

Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform

Brian MacKenna, Nicholas A. Kennedy, Amir Mehrkar et al. · The Lancet Rheumatology · 2022 · 110 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13

Trends and clinical characteristics of COVID-19 vaccine recipients: a federated analysis of 57.9 million patients’ primary care records in situ using OpenSAFELY

Helen J Curtis, Peter Inglesby, Caroline E Morton et al. · medRxiv · 2021 · 99 citations · Full text

Public Health, Health Informatics, Public Health Informatics +17

Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform

Linda Nab, Edward P K Parker, Colm Andrews et al. · The Lancet Public Health · 2023 · 97 citations · Full text

Public Health, Health Sciences, Infectious Diseases +12

Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform

Bang Zheng, Amelia Green, John Tazare et al. · BMJ · 2022 · 96 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT)

Oliver Carlile, Andrew Briggs, Alasdair D Henderson et al. · The Lancet Regional Health - Europe · 2024 · 96 citations · Full text

Pharmacy, Health Sciences, Clinical Epidemiology +16